Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline: European Commission Authorizes Nimenix

04/27/2012 | 08:24am US/Eastern

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc
React to this article
Latest news on GLAXOSMITHKLINE PLC
08/28 GLAXOSMITHKLINE : JPML to Hear Zofran Lawsuit Consolidation Oral Arguments in Ne..
08/26 GLAXOSMITHKLINE : GSK announces NEJM publication of Phase 3b/4 study of ambrisen..
08/24 NOVARTIS : Pharma to Acquire Rights to Ofatumumab for Auto-Immune Indications fr..
08/24 AstraZeneca names Genentech's Bohen as chief medical officer
08/21 NOVARTIS : could pay more than $1B for GlaxoSmithKline MS drug
08/21DJNOVARTIS : Correction to Glaxo Sells Rights to Auto-Immune Drug to Novartis
08/21DJGlaxo Sells Rights to Auto-Immune Drug to Novartis -- Update
08/21DJPfizer Late-Stage Meningitis B Drug Studies Meet Endpoints
08/21DJPfizer Late-Stage Meningitis B Drug Studies Meet Endpoints
08/21 GlaxoSmithKline sells multiply sclerosis treatment for $1bn
Advertisement
Chart
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Income Statement Evolution
More Financials